Armed with a fresh cash injection from backer Syncona, Freeline Therapeutics Ltd. has poached Alnylam Pharmaceuticals Inc.'s Theresa Heggie as CEO as the UK gene therapy firm makes plans to put its hemophilia B treatment into pivotal trials.
Freeline Bags Alnylam's Heggie As CEO
Hemophilia B Gene Therapy Advances
Syncona-backed Freeline has nabbed an "accomplished commercial leader" in Theresa Heggie to lead the company as it prepares to take FLT180a, its gene therapy for hemophilia B, into Phase III.
More from Blood and Clotting
• By
The Belgium-based firm will take the first-in-class drug, based on tick saliva, targets inflammation without increasing bleeding, into a Phase IIb trial is in preparation, supported by a new series B funding round.
• By
CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
Taiwan-based PharmaEssentia hopes to add essential thrombocytopenia to the label for its pegylated interferon product, already approved to treat polycythemia vera.